fda sets new hearing date for over-the-counter birth control
喀麦隆vs巴西波胆分析 welcomes the news that the fda has rescheduled an advisory committee meeting to review hra pharma’s application to switch opill, a progestin-only, daily birth control pill from prescription to over-the-counter status. the new dates - on may 9th and 10th - coincide with the 63rd anniversary of approval of the daily birth control pill, celebrated by advocates as #freethepill day.